首页 > 科学研究 > 研究团队

吴虹, 研究员


T: +86-10-62765646
E: hongwu@pku.edu.cn

北京市海淀区颐和园路5号北京大学金光生命科学大楼106号,100871

个人简介

  吴虹教授1983年毕业于北京医学院(现北京大学医学部)后入选CUSBEA项目于1984年赴美国哈佛大学医学院攻读博士学位,从师美国麻省理工学院Whitehead研究所Rudolf Jaenisch教授。1991年获得博士学位后在Whitehead研究所Harvey Lodish 课题组从事博士后研究工作。1996年起受聘于加州大学洛杉矶分校分子与医学药理学系助理教授直至终身讲席教授;期间任分子医学所主任、David Geffen医学院终身讲席教授。吴虹教授长期致力于肿瘤分子遗传学的研究,重点探讨抑癌基因在肿瘤发生、发展及耐药中的分子机制。她所领导的团队在抑癌基因信号传递、肿瘤干细胞及基因工程动物模型等研究方面做了大量的杰出工作,其研究成果对于发现肿瘤发生的分子机制以及肿瘤治疗的新途径有重大的理论及实际意义。截至2017年6月,吴虹教授发表SCI收录科学论文160余篇,引用2万余次。基于她在肿瘤分子遗传学领域的重大贡献及卓越成就,曾获得皮尤学者(Pew Scholar)、霍华德休斯助理研究员(HHMI Assistant Investigator)等多项奖励和荣誉,并于2010年当选为美国科学促进会会士(Fellow of American Association for the Advancement of Science),2016年当选为欧洲分子生物学组织(European Molecular Biology Organization, EMBO)外籍院士。

  2013年吴虹教授全职回国任北京大学生命科学学院讲席教授、北京大学生命科学学院院长,同时任北京大学-清华大学生命科学联合中心研究员、北京大学北京未来基因诊断高精尖创新中心研究员。吴虹课题组目前的主要研究方向为通过建立的PTEN缺失相关的多种肿瘤模型,应用分子遗传学、蛋白质组学、高通量测序、单细胞测序等手段研究PTEN信号通路与肿瘤发生发展的关系、筛选靶向药物、揭示肿瘤耐药机制。目前关心的主要科学问题如下:

  1. PTEN调控干细胞和肿瘤干细胞的分子遗传机制;

  2. PI3K与其他信号通路的相互作用在肿瘤发生、转移和耐药中的功能;

  3. 中国人群前列腺癌和T细胞急性淋巴细胞白血病基因组图谱。

  

  代表性论文

  1. Zhu, H., Zhang, L., Wu, Y., Dong, B., Guo, W., Wang, M., Yang, L., Fan, X., Tang, Y., Liu, N., Lei X., and Wu H*. (2018) T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1. eLife 7:e38314.

  2. Zou, Y., Qi, Z., Guo, W., Zhang, L., Ruscetti, M., Shenoy, T., Liu, N., and Wu, H*. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kalpha/beta/delta Inhibitor BAY1082439. Mol Cancer Ther 17(10): 2091-2099.

  3. Shenoy, T.R., Boysen, G., Wang, M.Y., Xu, Q.Z., Guo, W.L., Koh, F.M., Wang, C., Zhang, L.Z., Wang, Y., Gil, V., Aziz, S., Christova, R., Rodrigues, D.N., Crespo, M., Rescigno, P., Tunariu, N., Riisnaes, R., Zafeiriou, Z., Flohr, P., Yuan, W., Knight, E., Swain, A., Ramalho-Santos, M., Xu, D.Y., de Bono, J*. and Wu, H*. (2017) CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol 28(7):1495-1507.

  4. Ruscetti, M., Dadashian, E.L., Guo, W., Quach, B., Mulholland D.J., Park J.W., Tran, L.M., Kobayashi, N., Bianchi-Frias, D., Nelson, P.S., Xing, Y. and Wu, H*. (2016) HDAC Inhibition Impedes Epithelial-Mesenchymal Plasticity and Suppresses Metastatic, Castration-Resistant Prostate Cancer. Oncogene 35(29): 3781-3795.

  5. Ruscetti, M., Quach, B., Dadashian, E.L., Mulholland, D.J. and Wu, H*. (2015) Tracking and functional characterization of EMT and mesenchymal-like tumor cells in prostate cancer metastasis. Cancer Res 75(13):2749-59.

  6. Schubbert S, Cardenas A, Chen H, Garcia C, Guo W, Bradner JE, Wu H*. (2014)  Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T cell acute lymphoblastic leukemia. Cancer Res 74(23): 7048-59.

  7. Mulholland, D., Tran, M.L., Cai, H., Morim, A., Wang, S., Plaisier, S., Huang, J., Garraway, I., Graeber, T. and Wu, H*. (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19(6): 792-804.

  8. Guo, W., Schubbert, S., Chen, J-Y, Valamehr, V., Mosessian, S., Shi, H., Garcia, C., Theodoro, M.F., Varella-Garcia, M and Wu, H*. (2011) Suppression of leukemia and leukemia stem cell transformation. Proc. Natl. Acad. Sci. USA 108(4): 1409-1414.

  9. Tsutsui, H., Valamehr, B., Hindoyan, A., Qiao, R., Ding, X., Guo, S., Witte, O., Liu, X., Ho, C.M*., and Wu, H*. (2011) An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nature Communications 2:167.

  10. Gregorian, G., Nakashima, J., Dry, S.M., Nghiemphu, P.L., Smith, K.B., Ao, Y., Dang, J., Lawson, G., Mellinghoff, I.K., Mischel, P.S., Phelps, M*., Parada, L., Liu, X., Sofroniew, M.V., Eilber, F.C. and Wu, H*. (2009) PTEN Dosage is Essential for Neurofibroma Development and Malignant Transformation.  Proc. Natl. Acad. Sci. USA 106(46): 19479-84.

  11. Guo, W., Lasky, J, Chang, C., Mosessian, S., Lewis, X., Xiao, Y., Yeh, J., Chen, J., Iruela-Arispe, L., Varella-Garcia, M. and Wu, H*. (2008) Multi-genetic events collaboratively to Pten-null leukaemia stem-cell formation. Nature 453: 529-533.

  12. Lei, Q., Jiao, J., Xin, L., Chang, C., Wang, S., Gao, J., Gleave, M.E., Witte, O., Liu, X. and Wu, H*. (2006) NKX3.1 stabilizes p53, inhibits AKT activation and delays prostate cancer initiation caused by PTEN loss. Cancer Cell 9(5): 367-378.

  13. Groszer, M., Erickson, R., Scripture-Adams, D., Dougherty, J., LeBelle, J., Zack, J., Geschwind, D., Liu, X., Kornblum, H*. and Wu, H*. (2006) PTEN Negatively Regulates Neural Stem Cell Self-Renewal by Modulating G0-G1 Cell Cycle Entry. Proc. Natl. Acad. Sci. USA 103(1): 111-116. 

  14. Wang, S., Garcia, A., Wu, M., Lawson, D., Witte, O*. and Wu, H*. (2006) Ptendeletion leads to the expansion of prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. USA 103(5): 1480-1485.

  15. Freeman, D., Wei, G., Li, H., Li, A., Lesche, R., Whale, A., Martinez-Diaz, H., Rozengurt, N., Liu, X*. and Wu, H*. (2003) PTEN Tumor Suppressor Gene Regulates p53 Through Both MDM2-Dependent and Independent Mechanisms. Cancer Cell 3(2):117-129.